Genor BioPharma Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
17
- Investments
-
5
- Share Price
-
$0.41
- (As of Tuesday Closing)
Genor BioPharma General Information
Description
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Contact Information
Website
www.genorbio.comCorporate Office
- Building 3, 1690 Zhangheng Road, Pudong New Area
- Shanghai, 200009
- China
Corporate Office
- Building 3, 1690 Zhangheng Road, Pudong New Area
- Shanghai, 200009
- China
Genor BioPharma Stock Performance
As of 30-Dec-2025, Genor BioPharma’s stock price is $0.41. Its current market cap is $824M with 2.01B shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.41 | $0.39 | $0.21 - $0.72 | $824M | 2.01B | 806K |
Genor BioPharma Financials Summary
As of 30-Jun-2025, Genor BioPharma has a trailing 12-month revenue of $31M.
|
In Thousands, USD |
TTM 30-Jun-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 17,547 | (26,342) | (106,720) | (98,162) |
| Revenue | 31,038 | 28,741 | 0 | 2,366 |
| EBITDA | 854 | (6,897) | (88,961) | (104,536) |
| Net Income | 4,007 | (7,147) | (95,318) | (108,428) |
| Total Assets | 184,695 | 176,673 | 204,113 | 306,566 |
| Total Debt | 104 | 125 | 1,009 | 4,143 |
Genor BioPharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genor BioPharma Comparisons
Industry
Financing
Details
Genor BioPharma Competitors (3)
One of Genor BioPharma’s 3 competitors is BeOne Medicines, a Formerly PE-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Innovent Biologics | Formerly VC-backed | Suzhou, China | ||||
| Immatics | Formerly VC-backed | Tuebingen, Germany |
Genor BioPharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Genor BioPharma Patents
Genor BioPharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026011331-A1 | Stable bispecific antibody composition | Pending | 10-Jul-2024 | ||
| EP-4743116-A1 | Anti-pd-1/ctla-4/tigit trispecific antibodies and use thereof | Pending | 14-Jul-2023 | ||
| WO-2025016012-A1 | Anti-pd-1/ctla-4/tigit trispecific antibodies and use thereof | Inactive | 14-Jul-2023 | ||
| JP-2026525575-A | Anti-pd-1/ctla-4/tigit trispecific antibody and its use | Pending | 14-Jul-2023 | ||
| AU-2024292559-A1 | Anti-pd-1/ctla-4/vegf antibodies and use thereof | Pending | 14-Jul-2023 | C07K16/2818 |
Genor BioPharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Genor BioPharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Genor BioPharma Investments & Acquisitions (5)
Genor BioPharma’s most recent deal was a Reverse Merger with Edding Genor Group Holdings Limited. The deal was made on 22-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Edding Genor Group Holdings Limited | 22-Dec-2025 | Reverse Merger | Pharmaceuticals | ||
| VibroniX (Diagnostic Equipment) | 30-May-2022 | Corporate | Diagnostic Equipment | ||
| Tiantong Ruihong Technology | 03-Nov-2021 | Early Stage VC | General Purpose Semiconductors | ||
| Sanhejiuye | 08-Dec-2017 | Secondary Transaction - Private | Beverages | ||
| Jsolar Incorporated | 30-Jun-2015 | Early Stage VC | Alternative Energy Equipment |
Genor BioPharma Exits (4)
Genor BioPharma’s most recent exit was on 30-May-2022 from VibroniX (Diagnostic Equipment). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| VibroniX (Diagnostic Equipment) | 30-May-2022 | Completed |
|
||
| Tiantong Ruihong Technology | 03-Nov-2021 | Completed |
|
||
| Sanhejiuye | 08-Dec-2017 | Completed |
|
||
| Jsolar Incorporated | 30-Jun-2015 | Early Stage VC | Completed |
Genor BioPharma FAQs
-
When was Genor BioPharma founded?
Genor BioPharma was founded in 2007.
-
Where is Genor BioPharma headquartered?
Genor BioPharma is headquartered in Shanghai, China.
-
What is the size of Genor BioPharma?
Genor BioPharma has 17 total employees.
-
What industry is Genor BioPharma in?
Genor BioPharma’s primary industry is Biotechnology.
-
Is Genor BioPharma a private or public company?
Genor BioPharma is a Public company.
-
What is the current stock price of Genor BioPharma?
As of 30-Dec-2025 the stock price of Genor BioPharma is $0.41.
-
What is the current market cap of Genor BioPharma?
The current market capitalization of Genor BioPharma is $824M.
-
What is Genor BioPharma’s current revenue?
The trailing twelve month revenue for Genor BioPharma is $31M.
-
Who are Genor BioPharma’s competitors?
BeOne Medicines, Innovent Biologics, and Immatics are competitors of Genor BioPharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
